Pharmaceutical filing citing a Sleep Medicine paper — Incannex Healthcare, 2025-05-14
Incannex HealthcareIncannex HealthcareNASDAQ IXHL
Filings SEC · Quote Yahoo cited a paper published in Sleep Medicine in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It noted where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, it submits a current report to the Securities and Exchange Commission, called 8-K. The item numbers of the document submitted by Incannex Healthcare on 2025-05-14 were 8.01 Other Events · 9.01 Financial Statements and Exhibits. The company cited a paper published in Sleep Medicine in the attached press release. Translating the sentence in the original document that cites the paper verbatim, it reads as follows.
Elevated HB has been strongly correlated with cardiovascular morbidity and all-cause mortality, reinforcing the therapeutic potential of IHL-42X as a once-daily, oral treatment capable of addressing a critical unmet need in sleep medicine.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company's claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has only read the abstract, cannot provide an answer.
The scope of the paper mentioned in the abstract is limited to this extent.
The title of the paper is The impact of acetazolamide and dronabinol on the physiological endotypes responsible for obstructive sleep apnea and it was published in Sleep Medicine on 2025-04-28. The authors are affiliated with the Australian Regenerative Medicine Institute · Monash University · West Australian Sleep Disorders Research Institute · Novita Healthcare (Australia). The summary included at the beginning of the paper is called abstract. This article has read only up to this point. The paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, so it is of a different grade from a full-text reading and a definitive judgment.
Data from a clinical trial in which patients with obstructive sleep apnea, a condition where the airway is blocked during sleep, were given a combination of acetazolamide and dronabinol in three different doses were re-analyzed. Loop gain, which indicates how sensitive respiratory control is, decreased as the dose increased, and this reduction was linked to a decrease in the apnea index only at the high dose. The ease with which the airway collapses improved only at the low dose, while the arousal threshold and muscle compensation showed no change. This post-hoc analysis of the original trial suggests different mechanisms of action at each dose, but this interpretation is a proposal, not a confirmation.
The unanswered questions remain in the full text and appendices. This article leaves the gaps as they are. Readers are invited to compare the two citations above to determine which sentence in the abstract the company cited.
One month later, the stock price was in the bottom quarter of the sample.
The portion of returns not explained by market movement is called excess return. Dates are counted in trading days, which are the days the stock market is open. On a calendar, 20 trading days are roughly a month. The excess returns for the day of the announcement and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the announcement | −42.7% | The extent of movement before the filing |
| On the filing day | +721.4% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | +647.9% | One week |
| Accumulated over +1 to +20 trading days | −69.2% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of -69.2% in this case is in the bottom quarter, corresponding to 0% from the bottom among 142 samples.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.8% | −20.1% | −6.9% | +5.5% | +19.5% | −69.2% |
Half of the sample falls between the two central marks on the chart. One checks the chart to see whether this case lies within or outside the range. The sample collects cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules applicable to future cases.
After the filing, the company issued such documents.
Three 8-K filings issued by the company after the filing date are listed by item number only. In 8-K filings without titles, the item number indicates the type of content. Whether it was an earnings announcement or a contract can be identified by the number. The specific event is read in the original text of each link.
- 2025-05-15 8-K Item 1.01, 9.01 — Material Contract Execution · Financial Statements · Attached Documents
- 2025-05-15 8-K Item 8.01, 9.01 — Other Events · Financial Statements · Exhibits
- 2025-05-16 8-K Item 8.01, 9.01 — Other Events · Financial Statements · Exhibits
What this article does not answer
This article, based on abstracts, cannot answer what methods the paper used, what it reviewed, or what extent it demonstrated. How many times the cited paper was referenced afterward can be verified again through OpenAlexOpenAlex
Data source · Website citation counts. The next thing to look at is whether the company's next 8-K filing cites the same paper again.
Glossary
- 8-K
- A voluntary report submitted to the Securities and Exchange Commission when a U.S. listed company has something to inform shareholders. Types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder after subtracting the overall market return from the stock return. It is used to see the movement of the company alone by removing the part where the market as a whole rises or falls.
- Trading day
- A date counting only the days the stock market is open. Since weekends and holidays are excluded, 20 trading days are about a month in the calendar.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.